Sector
PharmaceuticalsOpen
₹68.4Prev. Close
₹70.05Turnover(Lac.)
₹16.77Day's High
₹75.5Day's Low
₹68.452 Week's High
₹98.3752 Week's Low
₹56Book Value
₹33.17Face Value
₹10Mkt Cap (₹ Cr.)
21.68P/E
28.02EPS
2.5Divi. Yield
028 Aug 2023
12:00 AM
AGM
Announcement Date: 28 Aug, 2023
23 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
28 Aug 2023
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 2.99 | 2.99 | 2.99 | 2.99 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 6.18 | 5.61 | 4.8 | 3.97 |
Net Worth | 9.17 | 8.6 | 7.79 | 6.96 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 13.94 | 14.83 | 6.84 | 6.43 |
yoy growth (%) | -5.95 | 116.75 | 6.26 | -9.32 |
Raw materials | -10.28 | -11.44 | -4.73 | -3.97 |
As % of sales | 73.74 | 77.16 | 69.16 | 61.68 |
Employee costs | -1.09 | -1.09 | -0.79 | -0.69 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 1.05 | 0.71 | 0.32 | 0.25 |
Depreciation | -0.14 | -0.17 | -0.13 | -0.13 |
Tax paid | -0.22 | -0.16 | -0.07 | -0.07 |
Working capital | 2.9 | -1.04 | -0.26 | -1.4 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -5.95 | 116.75 | 6.26 | -9.32 |
Op profit growth | 20.26 | 92.91 | 9.73 | 31.17 |
EBIT growth | 45.07 | 71.67 | 44.5 | 21.42 |
Net profit growth | 51.63 | 120.78 | 35.8 | 33.01 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,587.9 | 124.83 | 3,80,990.4 | 867.6 | 0.85 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,534.75 | 76.42 | 1,20,383.36 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,489.7 | 32.38 | 1,20,295.96 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,154.4 | 33.79 | 1,16,159.65 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,769.25 | 26.36 | 1,12,931.2 | 1,034.8 | 0.59 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Jagdish Agrawal
Director
Govind Gupta
Non Executive Director
Abha Agrawal
Director
Niranjan Agrawal
Director
Arvind Sapkal
Company Sec. & Compli. Officer
Srushti Pandya
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ishita Drugs & Industries Ltd
Summary
Ishita Drugs & Industries Limited was incorporated in Feb.92 by Jagdish Agarwal. The Company is engaged in the manufacture of various Activa Pharma Ingredients, drug intermediates, fine chemicals and excipient. It has a state-of-art manufacturing facility, in terms of reaction capabilities, quality control and environmental safety. The plant has been designed and constructed to meet GMP norms.The genesis of the Ishita Group in 1992 was the result of the entrepreneurial spirit of Mr. Jagdish Agrawal, who set up a reactive dye manufacturing unit in Ahmedabad. Buoyed by the growth of its first Venture, the Group made its maiden foray in the pharma sector in 1981 by setting up a small Bulk drugs plant at Surendranagar in Gujarat, to cater to the need of Pharma industry for Quality Products. The Bulk Drugs Industry at that point of time was highly dependent on costly imports and the growth was not achievable. The Company gradually formed a vertically integrated industry chain covering Drug Intermediates, Active Pharma Ingredients (APIs), excipients and finished dosage forms. The Group has 3 manufacturing facilities located in Gujarat, 2 for APIs and drug intermediates (at Ahmedabad and Surendranagar) and 1 for finished pharmaceutical formulations (at Mehsana).Thereafter, the Company set up a project to manufacture bulk drugs at Sanand, in the Ahmedabad district of Gujarat with an installed capacity of 408 tpa. Commercial production commenced in Jan.95. It established an in-house R
Read More
What is the Ishita Drugs & Industries Ltd share price today?
The Ishita Drugs & Industries Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹72.51 today.
What is the Market Cap of Ishita Drugs & Industries Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ishita Drugs & Industries Ltd is ₹21.68 Cr. as of 23 Jul ‘24
What is the PE and PB ratio of Ishita Drugs & Industries Ltd?
The PE and PB ratios of Ishita Drugs & Industries Ltd is 28.02 and 2.11 as of 23 Jul ‘24
What is the 52 Week High and Low of Ishita Drugs & Industries Ltd?
The 52-week high/low is the highest and lowest price at which a Ishita Drugs & Industries Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ishita Drugs & Industries Ltd is ₹56 and ₹98.37 as of 23 Jul ‘24
What is the CAGR of Ishita Drugs & Industries Ltd?
Ishita Drugs & Industries Ltd's CAGR for 5 Years at 31.16%, 3 Years at 16.24%, 1 Year at -9.03%, 6 Month at -4.76%, 3 Month at 0.86% and 1 Month at 2.14%.
What is the shareholding pattern of Ishita Drugs & Industries Ltd?
The shareholding pattern of Ishita Drugs & Industries Ltd is as follows:
Promoters - 49.42 %
Institutions - 0.00 %
Public - 50.58 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
